South Asian diabetic macular oedema treated with ranibizumab (ADMOR)—real-life experience

Abstract

Purpose Diabetic macular oedema (DMO) is a leading cause for visual impairment in the working age population in the UK. Ranibizumab has been shown to be effective in treatment of DMO in studies based on mainly Caucasian populations. This study reports the 12-month outcome in a cohort of South Asian subjects with DMO treated with ranibizumab. Methods DMO in 51 eyes of 41 South Asian patients was treated with ranibizumab 0.5 mg according to the modified DRCRnet protocol I. Visual acuity (VA) and central macular thickness (CMT) were recorded at baseline, 3, 6, and 12 months. Results were compared for eyes with different baseline visual acuities and different baseline macular thicknesses. Results Over the 12-month period, the mean ETDRS VA increased from 55.3 ± 13.4 letters to 63.8 ± 15.2 letters for all eyes. At 12 months, 70.6% eyes gained 5 or more letters acuity and 17.6% eyes gained 15 letters or more. During the same period, the mean CMT decreased from 532 ± 129 to 318 ± 136 μm. Eyes that had received previous laser treatments had a mean letter gain of 9.2 letters, compared with 8.5 for all eyes at 12 months. Conclusions Ranibizumab 0.5 mg is safe and effective at reversing vision loss due to DMO in patients of South Asian origin at 12 months. Ranibizumab treatment appears to be effective in patients with longstanding DMO who received prior laser treatments. Further studies are needed to define the longterm outcome in patients of different ethnicity and DMO.

Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting

“…In DME, differences in functional outcomes seem less significant than in nAMD between pivotal and real-life results. The ADMOR real-life study [ 21 ] has investigated the efficacy of ranibizumab in patients with DME in South Asia. The results showed a gain of +8.5 letters at 1 year with a mean number of 7 ± 2 IVI over the first year.…”

Outcomes after a 1-Year Treatment with Ranibizumab for Diabetic Macular Edema in a Clinical Setting

“…The ADMOR study [19] is the first real-life assessment of the efficacy of ranibizumab in South Asian patients with DME. The mean VA improvement found in the AD-MOR study was comparable to that found in our study, i.e.…”

The real life data of ranibizumab use among the diabetic macular edema patients in Turkey: Documenting the improvement with clinical optimization during three consecutive years

“…Pro re nata regimen has been commonly used in Turkey in the treatment of DME 10 . Studies from our country have revealed that the real life practice in regards to the visit and injection numbers was far from ideal 10, 11, 12, 13, 14, 15, 1610, 11…”